UNSPSC 51386010: Lexofenac

This classification denotes a nonsteroidal antiinflammatory drug, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3578QN1B5H. European Medicines Agency schedules Lexofenac in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08500MIG. Lexofenac generally arises in the molecular formula C14H14O3.

UNSPSC 51386010 Lexofenac is a Commodity code that nominally names a single non-steroidal anti-inflammatory drug product, but recent state and local procurement activity shows the code capturing broader pharmaceutical procurement — specifically naloxone, drug deactivation systems, generic multi-source pharmaceuticals, over-the-counter products, and direct-to-manufacturer prescription programs. The mismatch between the code's literal name and the actual scope of work being solicited suggests the taxonomy classification may be applied loosely by issuing bodies, or that the code is serving as a catch-all for pharmaceutical and related health-product contracting. The issuing bodies include county health departments (Seminole County, Florida), state health and human services agencies (Texas Health and Human Services Commission), and cooperative purchasing alliances spanning multiple states (Minnesota Multistate Cooperative Purchasing Alliance serving Minnesota, Oregon, and other participants). Activity shows a mix of competitive bid and RFP structures, with at least one exploratory RFI phase preceding formal procurement.

Recent activity concentrates in Florida, Texas, and the upper Midwest (Minnesota and Oregon). Seminole County, Florida released IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, response deadline July 26, 2023 (note: deadline date appears erroneous in source). The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for a direct-to-manufacturer prescription program without formal evaluation timelines or budget commitment at that exploratory stage. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, posted RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products with a response deadline of March 26, 2026, requiring vendors to work through three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, Morris & Dickson) and demonstrating pricing flexibility across multiple cost models with performance penalties of $200 to $1,500 per violation.